Patient's question:
High fever for 6 consecutive days, with temperatures of 38.5°C every night, peaking at 39.2°C. High fever and past treatment and effectiveness: received 4 days of Azithromycin intravenous infusion, switched to Erythromycin + Norfloxacin for 2 days. The high fever has been controlled, except for the blood test showing dual positivity for Mycoplasma...Doctor's answer:
It is a pathogen that exists between viruses and bacteria, without a cell wall. Clinical diagnosis requires erythromycin at a dose of 30–50 mg/(kg·d), divided into 4 oral doses. For adults, the dose is 1.5 g/d, divided into 3 oral doses, with a treatment course of 2–3 weeks. New macrolide drugs, such as roxithromycin, have fewer gastrointestinal side effects, high fluid concentrations, strong cellular penetration, long half-lives, and lower dosages (5–10 mg/(kg·d), divided into 2 oral doses). New drug azithromycin capsules start with a dose of 10 mg/(kg·d) on the first day, followed by 5 mg/(kg·d) for subsequent days, administered orally in a single dose, with a 5-day treatment course. Due to its long half-life, the drug's efficacy can persist for about 1 week after discontinuation. Norfloxacin or ciprofloxacin may also be used, with a dose of 0.4 g each time, twice daily, for a treatment course of 5–7 days.Survival care: Mycoplasma pneumoniae is caused by Mycoplasma pneumoniae and spreads through airborne transmission via oral and nasal secretions, which can lead to outbreaks and small epidemics. It is most common in children and adolescents, with higher prevalence in autumn and winter. The symptoms of this disease vary in severity, and some patients may show no obvious symptoms but be detected on chest X-rays. Most patients, in addition to general infectious symptoms, often experience headaches and persistent, irritable coughing. With effective treatment, most patients recover approximately within 2 weeks. After infection, humoral immunity is induced, and most adults have antibodies in their serum, so the disease rarely occurs. The effectiveness of Mycoplasma pneumoniae vaccines in prevention is still uncertain, but intranasal vaccination with attenuated live vaccines may provide some preventive benefits.